Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for well-known pharmaceutical companies globally [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 15, the company's stock price decreased by 0.54%, with a trading volume of 30.35 million yuan and a turnover rate of 1.61%, resulting in a total market capitalization of 3.996 billion yuan [1]. - The stock has seen a net inflow of 861,200 yuan from major investors today, with a ranking of 10 out of 52 in its industry, indicating a slight increase in major investor positions over the past two days [5][6].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including special fluorinated agents and various fluorination processes [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the Renminbi [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 10, the company's stock price decreased by 1.01%, with a trading volume of 33.1865 million yuan and a turnover rate of 1.75%, resulting in a total market capitalization of 4.019 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 2.4753 million yuan today, indicating a lack of clear control by major investors [5][6].

来源：新浪证券-红岸工作室 12月4日，金凯生科跌0.75%，成交额3249.27万元，换手率1.72%，总市值39.90亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-346.97万，占比0.11%，行业排名 ...

Core Viewpoint - The company JinKai Life Science has shown a positive performance in its stock price and financial results, benefiting from its focus on CDMO services for pharmaceutical companies and the depreciation of the RMB [1][4]. Business Overview - JinKai Life Science specializes in providing custom R&D and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [2][8]. - The company's main products include fluorinated and non-fluorinated CDMO services, with a significant focus on the production of intermediates for drugs like Semaglutide [2][3]. - As of November 20, the company reported a revenue of 488 million yuan for the first nine months of 2025, representing a year-on-year growth of 25.96%, and a net profit of 103 million yuan, up 163.24% [8]. Market Position - The company has a significant international presence, with overseas revenue accounting for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. - JinKai Life Science operates in the CRO (Contract Research Organization) sector, focusing on Alzheimer's-related intermediates and other pharmaceutical services [3][8]. Financial Performance - The company has a total market capitalization of 4.14 billion yuan and a trading volume of 47.6 million yuan on December 1, with a stock price increase of 0.76% [1]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Technical Analysis - The average trading cost of the stock is 37.04 yuan, with current price levels between resistance at 34.80 yuan and support at 33.51 yuan, indicating potential for short-term trading strategies [7].

Group 1 - The fluorochemical sector experienced a decline of 3.76%, ranking among the top losers in the concept sector, with stocks like Hainan Mining, Tianji Shares, and Tinci Materials hitting the daily limit down [1][2] - Major outflows of capital were observed in the fluorochemical sector, with a net outflow of 7.952 billion yuan, affecting 44 stocks, including significant outflows from Duofluoride and Tinci Materials [2][3] - The stocks with the largest capital outflows included Duofluoride with a net outflow of 1.436 billion yuan and Tinci Materials with 1.317 billion yuan [2][3] Group 2 - Among the stocks that saw capital inflows, Zhongchuan Special Gas, Nanda Optoelectronics, and Dongyangguang led with inflows of 49.76 million yuan, 47.70 million yuan, and 33.51 million yuan respectively [2][4] - The top decliners in the fluorochemical sector included Duofluoride and Tinci Materials, both experiencing a drop of 10% [3][4] - Other notable decliners included Hainan Mining and Kangpeng Technology, which also saw significant declines of 10.01% and 8.79% respectively [3][4]

Group 1 - The stock of Shida Shenghua has hit the daily limit down, indicating significant market sell-off [1] - Lichong Group and Xinzhou Bang have both dropped over 8%, reflecting a broader decline in the sector [1] - Other companies such as Tianci Materials, Zhongxin Fluorine Materials, Wehua New Materials, Yongtai Technology, and Yonghe Co. have also experienced declines [1]

Group 1 - The fluorochemical sector experienced significant declines, with companies like Lichong Group and Xinzhou Bang dropping over 8% [1] - Other companies in the sector, including Tianci Materials, Zhongxin Fluorine Materials, Weihua New Materials, Yongtai Technology, and Yonghe Co., also saw declines [1]

- The report introduces a "Total Heat Index" for monitoring market sentiment, which aggregates the browsing, self-selection, and click counts of individual stocks, normalized by their market share on the same day and multiplied by 10,000, with a value range of [0,10000][8] - The "Total Heat Index" is used as a proxy variable for "emotional heat" to track the sentiment of broad-based indices, industries, and concepts[8] - The report constructs a simple rotation strategy based on the weekly heat change rate (MA2) of broad-based indices, buying the index with the highest heat change rate at the end of each week, and staying out of the market if the highest change rate is in the "other" group[14] - The rotation strategy based on the heat change rate (MA2) of broad-based indices has an annualized return of 8.74% since 2017, with a maximum drawdown of 23.5%, and a return of 40.9% in 2025[17] - The report constructs two simple portfolios: a "Heat TOP" portfolio, which selects the top 10 stocks with the highest total heat from the top 5 concepts with the largest heat change rate each week, and a "BOTTOM" portfolio, which selects the bottom 10 stocks with the lowest total heat from the same concepts[32] - The "BOTTOM" portfolio historically achieves a certain excess return, with an annualized return of 15.71% and a maximum drawdown of 28.89%, and a return of 43.9% in 2025[34] - The "Total Heat Index" for broad-based indices includes the heat of the constituent stocks of the CSI 300, CSI 500, CSI 1000, and CSI 2000 indices, as well as the heat of stocks not included in these indices (the "other" group)[9] - The weekly heat change rate (MA2) of the "other" group is calculated and smoothed, and its relationship with the equal-weighted returns of the four broad-based indices is analyzed[12] - The weekly heat change rate (MA2) of the CSI 2000 index increased by 11.95% compared to the previous week, while the CSI 500 index decreased by 12.1%[17] - The weekly heat change rate (MA2) of the top 5 first-level industries with positive changes are comprehensive, textile and apparel, retail, food and beverage, and environmental protection, while the top 5 industries with negative changes are communication, electronics, defense and military, computer, and non-bank finance[28] - The weekly heat change rate (MA2) of the top 5 second-level industries with positive changes are pharmaceutical commerce, TV broadcasting II, beverage and dairy, power grid equipment, and hotel and catering[28] - The top 5 concepts with the largest heat change rate are dairy, artificial meat, organic silicon, fluorine chemical, and perovskite battery[29] - The historical valuation percentiles (rolling 5 years) of the CSI 300, CSI 500, and CSI 1000 indices are 85%, 97%, and 96%, respectively, as of November 14, 2025[42] - The first-level industries with current valuations in the top 80% historical percentiles since 2015 include comprehensive, power equipment, banking, light industry manufacturing, retail, electronics, steel, computer, pharmaceutical and biological, building materials, coal, defense and military, environmental protection, and basic chemicals[43] - The second-level industries with current valuations in the top 80% historical percentiles since 2015 include comprehensive, aerospace equipment, large state-owned banks, software development, biological products, steel raw materials, wind power equipment, chemical pharmaceuticals, environmental protection equipment, general steel, clothing and home textiles, tourism and scenic spots, rubber, airports, professional chains, decoration and building materials, semiconductors, lighting equipment, digital media, chemical fibers, other electronics, internet e-commerce, commercial vehicles, automotive services, diversified finance, and coal mining[45]

Core Viewpoint - The fluorochemical sector has shown significant growth, with a 4.50% increase, leading the concept sectors in terms of gains, driven by strong performances from several key stocks [1][2]. Group 1: Sector Performance - The fluorochemical concept sector increased by 4.50%, with 48 stocks rising, including notable gainers such as Kangpeng Technology and Taihe Technology, which hit the 20% limit up [1][2]. - Other stocks that reached the limit up include Furui Shares, Duofluor, and Shida Shenghua, while Xinzhou Bang, ST Lianchuang, and Hainan Mining also saw significant increases of 17.49%, 7.89%, and 7.64% respectively [1][2]. Group 2: Capital Flow - The fluorochemical sector attracted a net inflow of 4.089 billion yuan, with 35 stocks receiving net inflows, and 7 stocks exceeding 100 million yuan in net inflow [2]. - Tianqi Materials led the net inflow with 1.749 billion yuan, followed by Duofluor, Xinzhou Bang, and Yuntianhua with net inflows of 961 million yuan, 324 million yuan, and 281 million yuan respectively [2]. - The net inflow ratios were highest for Furui Shares, Tianqi Materials, and Kangpeng Technology, with rates of 57.34%, 26.46%, and 15.31% respectively [2].

Group 1 - The fluorochemical sector has seen a significant increase of 4.50%, leading the concept sectors in terms of growth, with 48 stocks rising, including notable gains from Kangpeng Technology and Taihe Technology, both reaching a 20% limit up [1] - Major stocks in the fluorochemical sector that hit the limit up include Furui Shares, Duofluor, and Shida Shenghua, while New Zhoubang, ST Lianchuang, and Hainan Mining also showed strong performance with increases of 17.49%, 7.89%, and 7.64% respectively [1] - The sector attracted a net inflow of 4.089 billion yuan from main funds, with 35 stocks receiving net inflows, and 7 stocks exceeding 100 million yuan in net inflows, led by Tianci Materials with 1.749 billion yuan [1] Group 2 - In terms of fund inflow ratios, Furui Shares, Tianci Materials, and Kangpeng Technology had the highest net inflow rates at 57.34%, 26.46%, and 15.31% respectively [2] - The top stocks by net inflow in the fluorochemical sector include Tianci Materials with a 10.00% increase and a turnover rate of 10.02%, followed by Duofluor with a 10.01% increase and a turnover rate of 23.90% [2][3] - Other notable stocks include New Zhoubang with a 17.49% increase and a turnover rate of 13.17%, and Yun Tianhua with a 3.64% increase and a turnover rate of 5.57% [2][3]